Filing Flows

Filing Flows › Companies › Zomedica › Cash flow

Zomedica cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$3.0M in Q3 2026 · −$11.9M over twelve months

Operating cash flow−$2.8M
Capital spending−$187K
Free cash flow−$3.0M
Cash conversion cycle155 days

Analysis

In Q3 2026, Zomedica generated −$2.8M of operating cash flow and spent $187K on capital projects, leaving free cash flow of −$3.0M. That is $1.7M more than in Q3 2025 (−$4.7M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$11.5M; the largest uses were operating cash flow ($11.5M), capital spending ($446K); besides operations, cash came from other investing ($11.7M); the cash balance fell by $215K.

Operating cash flow was −$2.8M against net income of −$3.2M. The largest differences: depreciation & amortization +$1.8M, receivables −$1.1M, prepaid and other assets −$670K.

Its cash conversion cycle was 155 days (receivables 58 + inventory 141 − payables 44).

Free cash flow

Zomedica: free cash flow by quarterZomedica: free cash flow by quarter−$5.1MQ4 2024−$6.9MQ1 2025−$5.6MQ2 2025−$4.7MQ3 2025−$1.0MQ4 2025−$5.3MQ1 2026−$2.6MQ2 2026−$3.0MQ3 2026
Operating cash flow less capital spending.
Zomedica: operating cash flow against capital spendingZomedica: operating cash flow against capital spendingOperating cash flowCapital spending−$4.5M$575KQ4 2024−$6.6M$280KQ1 2025−$5.4M$137KQ2 2025−$4.7M$43KQ3 2025−$899K$107KQ4 2025−$5.3M$60KQ1 2026−$2.6M$92KQ2 2026−$2.8M$187KQ3 2026
Latest (Q3 2026): Operating cash flow −$2.8M, Capital spending $187K.

Capital allocation, year by year

Zomedica: where the cash came from (up) and went (down), by fiscal yearZomedica: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow −$14.3MFY2021: Shares issued $201MFY2021: Capital spending −$147KFY2021: Acquisitions −$71.4M$201MFY2021FY2022: Operating cash flow −$11.7MFY2022: Capital spending −$787KFY2022: Acquisitions −$24.3MFY2022FY2023: Operating cash flow −$16.0MFY2023: Capital spending −$11.3MFY2023: Acquisitions −$24.0MFY2023FY2024: Operating cash flow −$23.6MFY2024: Capital spending −$5.2MFY2024FY2025: Operating cash flow −$17.6MFY2025: Capital spending −$567KFY2025
Over these 5 years operating cash flow totalled −$83.2M; the largest uses were acquisitions ($120M) and operating cash flow ($83.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$7.3M
Debtnone
Net cash$7.3M
Cash runway7 months

Zomedica is burning cash: its operations consume cash, a free cash flow of −$11.9M a year at the current rate against $7.3M of cash and investments: a runway of about 7 months before any new financing.

Where the cash came from and went

Zomedica: sources (+) and uses (−) of cash, Q3 2026Zomedica: sources (+) and uses (−) of cash, Q3 2026Other investing$3.0MOperating cash flow−$2.8MCapital spending−$187KCash drawn (+) / kept (−)−$87KExchange rates$20K
Zomedica: sources (+) and uses (−) of cash, TTM to Q3 2026Zomedica: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing$11.7MOperating cash flow−$11.5MCapital spending−$446KCash drawn (+) / kept (−)$215KExchange rates−$32K

From profit to cash

Zomedica: net income to operating cash flow, Q3 2026Zomedica: net income to operating cash flow, Q3 2026Net income−$3.2MDepreciation & amortization$1.8MStock-based pay−$38KDeferred taxes−$15KGains on disposals$96KReceivables−$1.1MInventory$286KPayables$268KAccrued liabilities−$273KDeferred revenue$30KPrepaid and other assets−$670KIncome taxes payable$10KOperating cash flow−$2.8M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20265814144155
Q2 20264815649155
Q1 20263815553140
Q4 20252715447134
Q3 20253119464160
Q2 20252521886157
Q1 20252822491161
Q4 20242420684146

Every quarter

QuarterOperating cash flowCapital spendingCash drawn (+) / kept (−)Free cash flow
Q3 2026−$2.8M−$187K−$87K−$3.0M
Q2 2026−$2.6M−$92K$2.2M−$2.6M
Q1 2026−$5.3M−$60K−$352K−$5.3M
Q4 2025−$899K−$107K−$1.5M−$1.0M
Q3 2025−$4.7M−$43K$633K−$4.7M
Q2 2025−$5.4M−$137K$708K−$5.6M
Q1 2025−$6.6M−$280K−$1.8M−$6.9M
Q4 2024−$4.5M−$575K$2.7M−$5.1M

Zomedica: income statement and cash flow

Zomedica, Q3 2026: revenue $9.9M (+22% year over year), operating margin -34.6%. The chart follows the revenue to costs, profit and cash.

Zomedica: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.